Castle Biosciences, Inc. · NASDAQ:CSTL
Castle Biosciences — Wells Fargo 2021 Healthcare Conference
11 slides from Castle Biosciences's conference presentation, Sep 9, 2021
Slide 1: Wells Fargo 2021 Healthcare Conference
W e l l s F a r g o 2 0 2 1 H e a l t h c a r e C o n f e r e n c e S e p t e m b e r 9 , 2 0 2 1 Tr a n s f o r m i n g t h e m a n a g e m e n t o f d e r m a t o l o g i c c o n d i t i o n s
Slide 2: Disclaimers: Forward-Looking Statements
D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amen
Slide 3: Leading Dermatologic Diagnostics Company
Transforming the management of skin cancer and other dermatologic diseases with high unmet clinical need Expansive Body of Evidence Suite of Dermatologic Prognostic And Diagnostic Tests Strong Financial Position Robust Pipeline L e a d i n g D e r m a t o l o g i c D i a g n o s t i c s C o m p a ny
Slide 4: Summary Q2 2021
F i n a n c i a l S u m m a r y 2 Q 2 0 2 1 2Q21 2Q20 Revenue $22.8M $12.7M Adj. Revenue1 $22.9M $10.4M Total GEP test reports2 7,007 3,314 Total Derm test reports2 6,539 3,008 Operating Cash Flow $(6.4)M $13.5M Adj. Operating Cash Flow1 $(4.3)M $3.3M Gross Margin 83% 83% Adj. Gross Margin1 84% 79%
Slide 5: Dermatologic test portfolio and addressable markets
Indication/ Test outcome Trade Name Reimbursement Status Peer-Reviewed Publications Primary Customers Initial Launch Targets Initial addressable market, patients2 Estimated U.S. TAM Cutaneous melanoma/ Risk of metastasis MCR, MCRA Commercial – in process 30+ Derms (including Mohs), Surgeons __ ~130k
Slide 6: Second quarter 2021 commentary and trends
• In the second quarter of 2021, we delivered 70% growth in DecisionDx-Melanoma test reports, compared to the second quarter of 2020 • We believe this is reflective of gains in both diagnoses of melanoma compared to 2020 as well as significant gains in market penetration • Although in certain geogra
Slide 7: Recent Achievements and Expected Future Milestones
Re c e n t A c h i e v e m e n t s A n d E x p e c t e d F u t u re M i l e s t o n e s 2 0 2 1 m i l e s t o n e s o n t r a c k Oct 2020: LCD expansion finalized for DecisionDx-Melanoma, effective date 12/6/20 2021: Potential draft LCD for DecisionDx-SCC and DecisionDx DiffDx-Melanoma 2020 2021 20
Slide 8: Thank You
THANK YOU
Slide 9: Use of Non-GAAP Measures (Unaudited)
U s e O f N o n - G A A P F i n a n c i a l M e a s u re s ( U n a u d i t e d ) 9 In this presentation, we use the metrics of Adjusted Revenue, Adjusted Gross Margin and Adjusted Operating Cash Flow, which are non-GAAP financial measures and are not calculated in accordance with generally accepted
Slide 10: Reconciliation of Non-GAAP Measures (Unaudited)
Re c o n c i l i a t i o n O f N o n - G A A P F i n a n c i a l M e a s u r e s ( U n a u d i t e d ) The table below presents the reconciliation of adjusted revenue and adjusted gross margin, which are non-GAAP measures. See "Use of Non-GAAP Financial Measures (UNAUDITED)" on the previous slide fo
Slide 11: Reconciliation of Non-GAAP Measures (Unaudited)
Re c o n c i l i a t i o n O f N o n - G A A P F i n a n c i a l M e a s u r e s ( U n a u d i t e d ) The table below presents the reconciliation of adjusted operating cash flow, which is a non-GAAP measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" on the previous slide for further info
Castle Biosciences — Wells Fargo 2021 Healthcare Conference on 6ix